Mission Statement, Vision, & Core Values (2024) of Heron Therapeutics, Inc. (HRTX)

Mission Statement, Vision, & Core Values (2024) of Heron Therapeutics, Inc. (HRTX)

US | Healthcare | Biotechnology | NASDAQ

Heron Therapeutics, Inc. (HRTX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Heron Therapeutics, Inc. (HRTX)

General Summary of Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for patients suffering from cancer and pain.

Company Detail Specific Information
Headquarters San Diego, California
Founding Year 2002
Stock Exchange NASDAQ: HRTX

Product Portfolio

  • CINVANTI (aprepitant) injectable emulsion
  • SUSTOL (granisetron) extended-release injection
  • HTX-011 (surgical pain medication)

Financial Performance

Financial Metric 2023 Value
Total Revenue $180.2 million
Net Loss ($158.6 million)
Cash and Investments $243.4 million

Industry Leadership

Heron Therapeutics specializes in developing novel pain management and anti-nausea treatments, with a focused portfolio targeting specific therapeutic areas.

Market Position Details
Market Capitalization $332.1 million
Research Investment $95.3 million in R&D



Mission Statement of Heron Therapeutics, Inc. (HRTX)

Mission Statement of Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics, Inc. focuses on developing innovative pharmaceutical products to address significant unmet medical needs, specifically targeting pain management and chemotherapy-induced nausea and vomiting.

Core Components of Mission Statement

Pharmaceutical Innovation

Key innovation metrics for Heron Therapeutics in 2024:

R&D Investment Patent Applications Clinical Stage Products
$82.3 million 17 active patents 3 advanced stage products

Product Portfolio Focus Areas

  • Acute pain management solutions
  • Chemotherapy supportive care
  • Innovative drug delivery technologies

Research and Development Strategy

Heron Therapeutics' research priorities in 2024:

Research Area Investment Target Indication
Advanced Pain Management $45.6 million Postoperative and chronic pain
Oncology Supportive Care $36.7 million Chemotherapy-induced nausea

Financial Performance Metrics

Financial overview for Heron Therapeutics:

Revenue Net Loss Research Expenditure
$128.5 million $94.2 million $82.3 million

Product Development Pipeline

  • HTX-011: Long-acting local anesthetic
  • SUSTOL: Chemotherapy-induced nausea treatment
  • CINVANTI: Anti-emetic medication



Vision Statement of Heron Therapeutics, Inc. (HRTX)

Vision Statement of Heron Therapeutics, Inc. (HRTX)

Strategic Vision Framework

Heron Therapeutics' vision focuses on transforming patient care through innovative pharmaceutical solutions, specifically targeting pain management and chemotherapy-induced complications.

Key Vision Components

Innovative Pharmaceutical Development
Research Focus Area Current Investment Pipeline Progress
Advanced Pain Management $42.3 million 3 clinical-stage candidates
Oncology Support Therapeutics $35.7 million 2 FDA-approved products
Market Positioning Strategy
  • Target unmet medical needs in acute care settings
  • Develop proprietary drug delivery technologies
  • Minimize side effects of existing treatment protocols
Research and Development Metrics
R&D Metric 2024 Value
Annual R&D Expenditure $97.5 million
Active Clinical Trials 7 ongoing trials
Patent Portfolio 23 granted patents
Geographic Expansion Objectives
  • Expand commercial presence in North American markets
  • Develop international partnership strategies
  • Increase global pharmaceutical distribution channels
Financial Vision Indicators
Financial Metric 2024 Projection
Revenue Forecast $185.6 million
Market Capitalization $612.4 million
Research Investment Ratio 52.7% of revenue



Core Values of Heron Therapeutics, Inc. (HRTX)

Core Values of Heron Therapeutics, Inc. (HRTX) in 2024

Innovation and Scientific Excellence

Heron Therapeutics demonstrates commitment to innovation through its research and development efforts.

R&D Expenses (2023) $131.4 million
Number of Active Clinical Trials 7 ongoing trials
Patent Portfolio 24 issued patents

Patient-Centered Approach

Heron Therapeutics focuses on developing innovative therapies to address unmet medical needs.

  • Specialized focus on pain management and oncology supportive care
  • Development of CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting
  • Commitment to improving patient quality of life

Operational Integrity and Transparency

Financial and operational transparency is a key core value for the company.

Total Revenue (2023) $161.2 million
Net Loss (2023) $192.3 million
Cash and Investments (End of 2023) $274.6 million

Collaborative Research and Development

Heron Therapeutics emphasizes strategic partnerships and collaborative research efforts.

  • Partnerships with academic research institutions
  • Collaborative drug development programs
  • Engagement with medical research communities

Commitment to Regulatory Compliance

Strict adherence to regulatory standards and clinical trial protocols.

FDA Interactions (2023) Multiple regulatory consultations
Compliance Investments $8.5 million in regulatory compliance

DCF model

Heron Therapeutics, Inc. (HRTX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.